Search

Your search keyword '"Virus Latency physiology"' showing total 694 results

Search Constraints

Start Over You searched for: Descriptor "Virus Latency physiology" Remove constraint Descriptor: "Virus Latency physiology"
694 results on '"Virus Latency physiology"'

Search Results

1. Epstein-Barr virus reactivation induces divergent abortive, reprogrammed, and host shutoff states by lytic progression.

2. Release of P-TEFb from the Super Elongation Complex promotes HIV-1 latency reversal.

3. The DNA loop release factor WAPL suppresses Epstein-Barr virus latent membrane protein expression to maintain the highly restricted latency I program.

4. A review of latency in the Alloherpesviridae family.

5. ORF48 is required for optimal lytic replication of Kaposi's sarcoma-associated herpesvirus.

6. The anti-apoptotic function of HSV-1 LAT in neuronal cell cultures but not its function during reactivation correlates with expression of two small non-coding RNAs, sncRNA1&2.

7. The histone methyltransferase SETD2 regulates HIV expression and latency.

8. Monocyte to macrophage differentiation and changes in cellular redox homeostasis promote cell type-specific HIV latency reactivation.

9. Humanized mice for studying HIV latency and potentially its eradication.

10. Dynamic modulation of the non-canonical NF-κB signaling pathway for HIV shock and kill.

11. The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency.

12. Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV.

13. Preexisting helminth challenge exacerbates infection and reactivation of gammaherpesvirus in tissue resident macrophages.

14. Binding of herpesvirus entry mediator (HVEM) and HSV-1 gD affect reactivation but not latency levels.

15. Wogonin inhibits latent HIV-1 reactivation by downregulating histone crotonylation.

16. HIV Tissue Reservoirs: Current Advances in Research.

17. Rethinking human cytomegalovirus latency reservoir.

18. The Intersection of Innate Immune Pathways with the Latent Herpes Simplex Virus Genome.

19. Bcl-xL is required to protect endothelial cells latently infected with KSHV from virus induced intrinsic apoptosis.

21. Deletion of the Transcriptional Coactivator HCF-1 In Vivo Impairs the Removal of Repressive Heterochromatin from Latent HSV Genomes and Suppresses the Initiation of Viral Reactivation.

22. The CMV-encoded G protein-coupled receptors M33 and US28 play pleiotropic roles in immune evasion and alter host T cell responses.

23. Functional diversity: update of the posttranslational modification of Epstein-Barr virus coding proteins.

24. CCL2: a Chemokine Potentially Promoting Early Seeding of the Latent HIV Reservoir.

25. Postinfection Metabolic Reprogramming of the Murine Trigeminal Ganglion Limits Herpes Simplex Virus-1 Replication.

26. Knockout of signal peptide peptidase in the eye reduces HSV-1 replication and eye disease in ocularly infected mice.

27. [Reactivation of latent viruses in Neurology].

28. A Single Herpes Simplex Virus 1 Genome Reactivates from Individual Cells.

29. T Cell-Specific STAT1 Expression Promotes Lytic Replication and Supports the Establishment of Gammaherpesvirus Latent Reservoir in Splenic B Cells.

30. Transcriptome profiles of latently- and reactivated HIV-1 infected primary CD4 + T cells: A pooled data-analysis.

31. HIV-1 latency is established preferentially in minimally activated and non-dividing cells during productive infection of primary CD4 T cells.

32. STAT and Janus kinase targeting by human herpesvirus 8 interferon regulatory factor in the suppression of type-I interferon signaling.

33. Impact of Cultured Neuron Models on α-Herpesvirus Latency Research.

34. Absence of signal peptide peptidase in peripheral sensory neurons affects latency-reactivation in HSV-1 ocularly infected mice.

35. Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.

36. In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure.

37. Modeling HIV Latency in Astrocytes with the Human Neural Progenitor Cell Line HNSC.100.

38. Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal.

39. A Reliable Primary Cell Model for HIV Latency: The QUECEL (Quiescent Effector Cell Latency) Method.

40. An In Vitro System to Model the Establishment and Reactivation of HIV-1 Latency in Primary Human CD4+ T Cells.

41. Dynamics of latent HIV under clonal expansion.

42. Pathogenesis and virulence of herpes simplex virus.

43. Clonal Expansion of Infected CD4+ T Cells in People Living with HIV.

44. Recent Issues in Varicella-Zoster Virus Latency.

45. Stress-Induced Epstein-Barr Virus Reactivation.

46. Biogenesis of P-TEFb in CD4+ T cells to reverse HIV latency is mediated by protein kinase C (PKC)-independent signaling pathways.

47. The Landscape of IFN/ISG Signaling in HIV-1-Infected Macrophages and Its Possible Role in the HIV-1 Latency.

48. Transmission parameters of pepper whitefly-borne vein yellows virus (PeWBVYV) by Bemisia tabaci and identification of an insect protein with a putative role in polerovirus transmission.

49. Inhibition of polo-like kinase 1 (PLK1) facilitates reactivation of gamma-herpesviruses and their elimination.

50. Cleavage and Polyadenylation Specificity Factor 6 Is Required for Efficient HIV-1 Latency Reversal.

Catalog

Books, media, physical & digital resources